In the evolving landscape of innovative therapeutics, Radiopharmaceuticals stand out as a powerful modality to diagnose, target and treat disease at the molecular level. This excitement is being reflected by clinical data and deployment of investment capital alike. The launches of PLUVICTO and LUTATHERA by Novartis have shown improved outcomes over traditional standards of care, with the former approaching blockbuster status in 2023 as it gains traction in oncology markets.
In the evolving landscape of innovative therapeutics, radiopharmaceuticals stand out as a powerful modality to diagnose, target and treat disease at the molecular level. This excitement is being refected by clinical data and deployment of investment capital alike.This report gives an overview of the global radiopharmaceutical markets and dynamics, in which also Belgium plays an important role with an internationally recognised ecosystem of nuclear medicine.
The global Radiopharmaceuticals market is set to reach nearly $14bn by 2033, growing 8-10% year-on-year
Given their utility in precision oncology, and potentially other therapeutic areas, we believe that Radiopharmaceuticals and their surrounding tools and services afford credible investment opportunities to both Pharma and financial investors. However, as with all classes of innovative therapeutics, the widespread adoption of Radiopharmaceuticals will only be made possible with accompanied progress in their manufacturing, distribution and storage and incorporation into clinical care pathways. Therefore, actionable areas in this space include clinical-stage Radiopharmaceutical companies, specialized CDMOs and logistics solutions providers.
In our view, Radiopharmaceuticals are a potentially attractive investment area owing to their status as a protected channel with a high barrier to entry and a clear market need for scaled tools and services to serve growing demand. However, to fully realize the value of this modality, regulatory (both from a medical and nuclear standpoint), safety and logistical challenges must be anticipated and mitigated.
Explore
Connect with us
- Find office locations kpmg.findOfficeLocations
- kpmg.emailUs
- Social media @ KPMG kpmg.socialMedia
